Agenus shared a post on LinkedIn:
“We’re excited to share that four Agenus abstracts have been accepted for presentation at ESMO25 (Berlin, October 17–21), highlighting clinical progress with our botensilimab plus balstilimab immunotherapy programs.
The Highlight:
An oral presentation featuring emerging survival plateaus in 343 patients with refractory metastatic solid tumors across five tumor types.
Additional Presentations Include:
Investigator-sponsored studies in cervical cancer, MSS metastatic colorectal cancer, and non-melanoma skin cancers, underscoring the broad potential of our innovative combinations in difficult-to-treat cancers.
Save the dates and learn more.”
More posts featuring Agenus.